Aadi Bioscienceincis A Late Stage Precision Oncology Company Dedicated To Developing Therapies For Genetically Defined Cancersthe Company Focuses On Improving The Lives Of Patients With Mtor Driven Diseases By Creating Targeted Treatmentsaadi Bioscience S Lead Productfyarronab Sirolimus Is An Mtor Inhibitor Designed For Adult Patients With Locally Advanced Unresectable Or Metastatic Malignant Perivascular Epithelioid Cell Tumorpecoma In Addition To Fyarrothe Company Has Initiated A Tumor Agnostic Phase Ii Studyprecision 1To Explore Its Applications In Patients With Tuberous Sclerosis Complex 1 And 2Tsc1 And Tsc2Alterationsaadi Bioscience Is Headquartered In Morristownnew Jerseyand Employs Around 40 Peopleas Of March 2025The Company Has Rebranded To Whitehawk Therapeuticsinc Which May Lead To Further Developments In Its Operational Focus
